durvalumab

December 8, 2017December 8, 2017

FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns

News

The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial hold in September 2017, ... Read more

September 8, 2017December 8, 2017

Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials

News

The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with immunomodulatory drugs as a treatment ... Read more

September 8, 2017September 10, 2017

FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths

News

The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer therapy for multiple myeloma. The ... Read more